Miró JM - Search Results

1

Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.

Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M. Bermejo M, et al. Among authors: miro jm. Biochem Pharmacol. 2018 Oct;156:248-264. doi: 10.1016/j.bcp.2018.08.031. Epub 2018 Aug 22. Biochem Pharmacol. 2018. PMID: 30142322

2

Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection.

García F, Plana M, Mestre G, Arnedo M, Gil C, Miró JM, Cruceta A, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: miro jm. AIDS. 2002 Sep 6;16(13):1761-5. doi: 10.1097/00002030-200209060-00008. AIDS. 2002. PMID: 12218387

3

Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression.

Soriano A, Martínez C, García F, Plana M, Palou E, Lejeune M, Aróstegui JI, De Lazzari E, Rodriguez C, Barrasa A, Lorenzo JI, Alcamí J, del Romero J, Miró JM, Gatell JM, Gallart T. Soriano A, et al. Among authors: miro jm. J Infect Dis. 2002 Oct 1;186(7):922-31. doi: 10.1086/343741. Epub 2002 Sep 13. J Infect Dis. 2002. PMID: 12232832

4

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.

García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: miro jm. AIDS. 2003 Jan 3;17(1):43-51. doi: 10.1097/00002030-200301030-00007. AIDS. 2003. PMID: 12478068 Clinical Trial.

5

Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis.

Garcia F, Plana M, Mestre G, Cruceta A, Martinez E, Miró JM, Mallolas J, Tuset M, Pumorola T, Gallart T, Gatell JM. Garcia F, et al. Among authors: miro jm. Antivir Ther. 2002 Sep;7(3):195-7. Antivir Ther. 2002. PMID: 12487387 Clinical Trial.

6

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM. Vidal C, et al. Among authors: miro jm. Antivir Ther. 2002 Dec;7(4):283-7. Antivir Ther. 2002. PMID: 12553483 Clinical Trial.

7

Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.

Navarrete P, Morente V, García F, Alós L, Arnedo M, Plana M, Gil C, Caballero M, Miró JM, Martínez E, Fumero E, Castro P, Blanco JL, Mallolas J, Blanch JL, Cruceta A, Mestre G, Pumarola T, Gallart T, Gatell JM. Navarrete P, et al. Among authors: miro jm. Antivir Ther. 2003 Dec;8(6):635-7. Antivir Ther. 2003. PMID: 14760898

8

Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM. Plana M, et al. Among authors: miro jm. Antivir Ther. 2004 Apr;9(2):197-204. Antivir Ther. 2004. PMID: 15134181 Clinical Trial.

9

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: miro jm. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13. doi: 10.1097/00126334-200406010-00007. J Acquir Immune Defic Syndr. 2004. PMID: 15167289

10

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.

Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Plana M, et al. Among authors: miro jm. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9. doi: 10.1097/00126334-200407010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15213562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

972 results

Search Page